Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Pulmonary Hypertension Modality of Death and Validation of REVEAL Risk Score
Pulmonary Arterial Hypertension (PAH) is a chronic disease characterized by a progressive increase in pulmonary vascular resistance (PVR), which leads to right ventricular (RV) failure, and ultimately death.
- Trial name
- ASPYRE-1 (NCT04677608)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- iPHNET (italian Pulmonary Hypertension NETwork)
HIV Infections, Hypertension
ENHANCE-EvideNce Led Co-created HeAlth Systems interventioNs for MLTCs CarE
The goal of this study is to determine the effect of the ENHANCE intervention in improving clinical outcomes and evaluating the effects of the intervention on implementation processes and outcomes.
- Conditions
- HIV Infections, Hypertension, Diabetes Mellitus, Asthma
- Trial name
- ENHANCE (NCT06248190)
- Testing
- ENHANCE intervention (health systems)
- Where
- 32 sites in South Africa
- Volunteers
- 1,837 people
- Sponsor
- University of KwaZulu
Systemic Sclerosis, Pulmonary Hypertension
Evaluating Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package- the Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa…
- Trial name
- NCT02339961
- Testing
- Ultrasound radiation
- Sponsor
- Echosense Ltd.
High Altitude, Healthy
Assessment of Six-minute Walking Distance Between Sea Level LA vs. High Altitude HA After Re-ascent in Healthy Individuals
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on six-minute walking distance and other scores in healthy individuals, who live…
- Conditions
- High Altitude, Healthy, Healthy Adult, Six-minute Walk Test
- Trial name
- NCT07797088
- Testing
- Re-Ascent sea level to 2850m
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Artery Hypertension
Potts-shunt for the Treatment of Pediatric Patients With Severe Pulmonary Hypertension
This is a multi-center, perspective, and exploratory study aimed at evaluating the 3-years clinical outcome of Potts-shunt procedure for pediatric patients with severe pulmonary artery hypertension (PAH).
- Trial name
- NCT06429579
- Testing
- Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy, Only conventional drug therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- China National Center for Cardiovascular Diseases
Arterial Pulmonary Hypertension (PAH)
Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are…
- Trial name
- NCT06753981
- Testing
- Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qianfoshan Hospital
Pulmonary Arterial Hypertension
A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
This multicenter, open label, Phase 2a study is designed to evaluate the effect of inhaled RT234 delivered in a dose escalation manner on the change in pulmonary vascular resistance (PVR) in subjects with Pulmonary Arterial…
- Trial name
- NCT05343637
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
- Where
- 3 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Respira Therapeutics, Inc.
Pulmonary Arterial Hypertension, Insulin Resistance
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
The purpose of this study is to investigate the extent to which diet and exercise may improve PAH through the modulation of insulin sensitivity.
- Trial name
- NCT03288025
- Testing
- Nutrition and Exercise
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- The Cleveland Clinic
COPD (With - Without Rehabilitation), Diffuse Interstitial Lung Diseases
Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases
The purpose of this study is the psychometric validation of a self-administered dyspnea questionnaire, usable in clinical practice in order to assess dyspnea and its impact on patients with chronic respiratory diseases.
- Conditions
- COPD (With - Without Rehabilitation), Diffuse Interstitial Lung Diseases, Pulmonary Arterial Hypertension Primary or Secondary (Post Embolic .....), Cystic Fibrosis of the Adult
- Trial name
- DYSLIM (NCT02229994)
- Testing
- Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.
- Where
- France
- Volunteers
- 199 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Refractory Lupus Nephritis, Systemic Sclerosis
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), primary Sjogren syndrome combined with pulmonary artery hypertension…
- Conditions
- Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, Other Autoimmune Diseases (AID)
- Trial name
- NCT06947460
- Testing
- CD19-BCMA CAR-T cells infusion
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing GoBroad Hospital
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Rutgers University Study of the Genetics of Pulmonary Hypertension
The goal of this observational study is to learn more about how genes impact the risk of pulmonary hypertension. Anyone 18 or older living in the US is eligible, and a diagnosis of PH is NOT required.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
- Trial name
- RUGCC-PH (NCT07217522)
- Testing
- Saliva sample, Health surveys
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Healthy Volunteers, Pulmonary Arterial Hypertension
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
- Trial name
- NCT06649110
- Testing
- LTP
- Where
- 87 sites in United States, Argentina and 16 more
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension, Exercise Training
Home-based Exercise Training in Patients With Pulmonary Arterial Hypertension: Effect on Skeletal Muscular Function and Metabolism
Pulmonary Arterial Hypertension has gone from a disease that causes rapid death to a more chronic condition. Yet, improved survival is associated with major challenges for clinicians as most patients remain with poor quality of…
- Conditions
- Pulmonary Arterial Hypertension, Exercise Training, Home-based Rehabilitation, Exercise Capacity
- Trial name
- NCT04241497
- Testing
- Home-based rehabilitation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Laval University
Pulmonary Arterial Hypertension
Assessing the Utility of Submaximal CPET in Treatment Management of PAH
Pulmonary hypertension (PH) is associated with worsening breathlessness and exercise capacity, right-heart failure, and adverse outcomes including increased mortality.
- Trial name
- NCT05977933
- Testing
- Shape II CPET
- Where
- 6 sites in United States
- Volunteers
- 550 people
- Sponsor
- Shape Medical Systems, Inc.
Pulmonary Hypertension
Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of escitalopram (30 mg/day) in two parallel groups (randomization ratio, escitalopram 2/placebo 1).
- Trial name
- NCT00190333
- Testing
- escitalopram
- Where
- 9 sites in France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Arterial Hypertension
A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
This study is an international, open-label, multi-center, Phase II, multiple dose, dose-finding study to investigate the safety, tolerability and pharmacokinetic characteristics of BPS-MR tablets in male and female patients with…
- Trial name
- NCT00781885
- Testing
- Beraprost sodium modified release
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 19 people
- Sponsor
- Lung Biotechnology PBC
Pulmonary Arterial Hypertension
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.
- Trial name
- NCT04816604
- Testing
- GB002 (seralutinib), Generic Dry Powder Inhaler
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 74 people
- Sponsor
- Gossamer Bio USA, Inc.
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Total Pulmonary Resistance sPAP/CO Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in patients with…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, High Altitude, Echocardiography
- Trial name
- NCT07804693
- Testing
- Re-Ascent from sea level to 2850m
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Hypertension, Hypertension, Pulmonary Arterial
Real-World Study of PADN for the Treatment of PAH
Real-World Study of PADN for the Treatment of PAH
- Trial name
- NCT07039604
- Testing
- Enhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Pulnovo Medical (Wuxi) Co., Ltd.
Pulmonary Arterial Hypertension
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
The objectives of this study are to evaluate the safety of RT234 and the effects of RT234 on exercise capacity as assessed by Cardiopulmonary Exercise Testing (CPET) and six minute walk testing (6MWT) as well as exertional…
- Trial name
- VIPAH-PRN_2B (NCT04266197)
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)
- Where
- 26 sites in United States
- Volunteers
- 42 people
- Sponsor
- Respira Therapeutics, Inc.